Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia

Trial Profile

Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance, symptoms and quality of life in patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency with and without anaemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Heart failure; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms The FAIR-HFpEF Trial
  • Most Recent Events

    • 09 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top